Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D06NST
|
||||
Former ID |
DNC008745
|
||||
Drug Name |
CYCLAZOCINE
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [538981] | ||
Structure |
Download2D MOL |
||||
Formula |
C18H25NO
|
||||
InChI |
InChI=1S/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3/t12?,17-,18+/m0/s1
|
||||
InChIKey |
YQYVFVRQLZMJKJ-OTLVQASYSA-N
|
||||
CAS Number |
CAS 7346-09-0
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Kappa-type opioid receptor | Target Info | Inhibitor | [525672] | |
Delta-type opioid receptor | Target Info | Inhibitor | [529871] | ||
Mu-type opioid receptor | Target Info | Inhibitor | [525672] | ||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
Enkephalin release | |||||
Opioid proenkephalin pathway | |||||
Opioid proopiomelanocortin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
References | |||||
Ref 525672 | J Med Chem. 2000 Jan 13;43(1):114-22.Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. | ||||
Ref 529871 | Bioorg Med Chem Lett. 2009 Jan 15;19(2):365-8. Epub 2008 Nov 24.Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.